(Q35169138)

6 August 2017

1 reference

title

Immunotherapy for lymphomas (English)

1 reference

6 August 2017

1 reference

John M Timmerman

1

1 reference

6 August 2017

publication date

1 June 2003

1 reference

International Journal of Hematology

6 August 2017

published in

1 reference

6 August 2017

volume

77

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

444-455

1 reference

Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens

6 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF02986612

Heat shock protein--peptide complexes as immunotherapy for human cancer

21 January 2018

1 reference

12 December 2020

Rituximab treatment results in impaired secondary humoral immune responsiveness.

1 reference

12 December 2020

Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants

1 reference

12 December 2020

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

12 December 2020

The host-tumor immune conflict: from immunosuppression to resistance and destruction

1 reference

12 December 2020

Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12

1 reference

12 December 2020

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

12 December 2020

A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

1 reference

12 December 2020

Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

1 reference

12 December 2020

TCR vaccines for active immunotherapy of T cell malignancies

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Fortifying B cells with CD154: an engaging tale of many hues

1 reference

12 December 2020

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

12 December 2020

Lysis of syngeneic tumor B cells by autoreactive cytotoxic T lymphocytes specific for a CD19 antigen-derived synthetic peptide

1 reference

12 December 2020

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

12 December 2020

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

12 December 2020

Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity

1 reference

12 December 2020

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

12 December 2020

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

12 December 2020

1 reference

12 December 2020

The history of the development of vaccines for the treatment of lymphoma.

1 reference

12 December 2020

Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: a therapeutic target

1 reference

12 December 2020

The promise of nucleic acid vaccines

1 reference

12 December 2020

Interleukin-12 in anti-tumor immunity and immunotherapy.

1 reference

12 December 2020

B cells inhibit induction of T cell-dependent tumor immunity.

1 reference

12 December 2020

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia

1 reference

12 December 2020

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

12 December 2020

Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization

1 reference

12 December 2020

Mechanisms and therapeutic applications of immune stimulatory cpG DNA.

1 reference

12 December 2020

Vaccine therapies for non-Hodgkin's lymphoma.

1 reference

12 December 2020

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

12 December 2020

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma

1 reference

12 December 2020

Interleukin-2 treatment in lymphoma: a phase II multicenter study

1 reference

12 December 2020

Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a

1 reference

12 December 2020

Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells

1 reference

12 December 2020

Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma

1 reference

12 December 2020

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

1 reference

12 December 2020

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

1 reference

12 December 2020

Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients

1 reference

12 December 2020

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

12 December 2020

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

1 reference

12 December 2020

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

12 December 2020

CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells

1 reference

12 December 2020

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

12 December 2020

Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines

1 reference

12 December 2020

Creating therapeutic cancer vaccines: notes from the battlefield

1 reference

12 December 2020

Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

12 December 2020

A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines

1 reference

12 December 2020

Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1

1 reference

12 December 2020

Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.

1 reference

12 December 2020

Dendritic cell vaccines for cancer immunotherapy

1 reference

12 December 2020

DNA fusion vaccines against B-cell tumors

1 reference

12 December 2020

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody

1 reference

12 December 2020

Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells

1 reference

12 December 2020

Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma--long-term results of a clinical trial.

1 reference

12 December 2020

Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits

1 reference

12 December 2020

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

1 reference

12 December 2020

Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma

1 reference

12 December 2020

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

1 reference

12 December 2020

Cancer vaccines for hematologic malignancies

1 reference

12 December 2020

Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer

1 reference

12 December 2020

TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.

1 reference

12 December 2020

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

1 reference

12 December 2020

Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

1 reference

12 December 2020

Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells

1 reference

12 December 2020

Immunobiology of dendritic cells

1 reference

12 December 2020

Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells

1 reference

12 December 2020

Phase I study of recombinant human CD40 ligand in cancer patients

1 reference

12 December 2020

Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

1 reference

12 December 2020

Active immunization against cancer with dendritic cells: the near future

1 reference

12 December 2020

DNA immunization induces protective immunity against B-cell lymphoma

1 reference

12 December 2020

The natural history of initially untreated low-grade non-Hodgkin's lymphomas

1 reference

12 December 2020

Antibody-directed therapies for hematological malignancies

1 reference

12 December 2020

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Vaccination with CD20 peptides induces a biologically active, specific immune response in mice.

1 reference

12 December 2020

Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine

1 reference

12 December 2020

Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.

1 reference

12 December 2020

Current and ongoing clinical development of immunotherapy in B-cell malignancies. Proceedings of a conference. January 2001, Kailua-Kona, Hawaii, USA

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF02986612

1 reference

6 August 2017

1 reference